JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.C600072200 on August 3, 2006

J. Biol. Chem., Vol. 281, Issue 38, 27674-27678, September 22, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/38/27674    most recent
C600072200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bennasser, Y.
Right arrow Articles by Jeang, K.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bennasser, Y.
Right arrow Articles by Jeang, K.-T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HIV-1 TAR RNA Subverts RNA Interference in Transfected Cells through Sequestration of TAR RNA-binding Protein, TRBP*

Yamina Bennasser, Man Lung Yeung, and Kuan-Teh Jeang1

From the Molecular Virology Section, Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bethesda, Maryland 20892-0460

Received for publication, March 22, 2006 , and in revised form, August 3, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
TAR RNA-binding protein, TRBP, was recently discovered to be an essential partner for Dicer and a crucial component of the RNA-induced silencing complex (RISC), a critical element of the RNA interference (RNAi) of the cell apparatus. Human TRBP was originally characterized and cloned 15 years ago based on its high affinity for binding the HIV-1 encoded leader RNA, TAR. RNAi is used, in part, by cells to defend against infection by viruses. Here, we report that transfected TAR RNA can attenuate the RNAi machinery in human cells. Our data suggest that TAR RNA sequesters TRBP rendering it unavailable for downstream Dicer-RISC complexes. TAR-induced inhibition of Dicer-RISC activity in transfected cells was partially relieved by exogenous expression of TRBP.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Cells mount several defenses against viral infection. Classically, cells react to infection by RNA viruses by triggering an interferon response (1). More recently, evidence suggests that a newly characterized activity, RNAi,2 provides an additional cellular defense against invading viral nucleic acids (2). Relevant to the mechanism of RNAi, long double-stranded RNA (dsRNA) originating from viruses are first recognized inside cells by an RNase III enzyme, Dicer, which cleaves the RNA into smaller 21- to 23-nucleotide duplexes, commonly termed small interfering RNAs (siRNA). For this activity, Dicer is assisted by a protein-protein complex formed with a cellular RNA-binding protein called TAR RNA-binding protein (TRBP) (3, 4). Dicer-TRBP is thought to shuttle the siRNA into a multiprotein RNA-induced silencing complex (RISC) to interact further with a protein called argonaute 2 (Ago2) (5). One strand of the siRNA duplex is then loaded onto Ago2 to serve as a guide RNA. Using this guide RNA, RISC becomes armed with the capacity to recognize target RNAs via base complementarity for purposes of enforcing sequence-specific degradation.

The RNAi machinery also processes structured dsRNA hairpins into microRNAs (miRNAs), another class of small RNAs that modulate gene expression (6). miRNAs are derived from transcription of large highly structured precursors (pri-miRNA) of ~70 nucleotides encoded by cellular genes. A primiRNA is processed in the nucleus of the cell into an imperfect shorter stem-loop structure (pre-miRNA) by Microprocessor, a large complex that includes Drosha and the RNA-binding protein DGCR8. Pre-miRNA is subsequently exported by Exportin 5 into the cytoplasm where it is additionally processed to maturity by Dicer. Similar to siRNA, one strand of the mature miRNA is then ferried by TRBP-Dicer to RISC to serve as a guide template. However, miRNA-armed RISC silences complementary mRNAs not by degradation but by virtue of being shunted into a ribosome-free cytoplasmic compartment called P-body (for "processing body") (7, 8). Hence, miRNAs primarily trigger translational repression, while siRNAs induce mRNA degradation (6).

While the complete protein composition of RISC still remains to be fully elucidated (9), in the preceding year, human TRBP protein has emerged as a newly discovered protein partner of Dicer and a contributory component (with Dicer, Ago2, and siRNA) (10–12) to RISC (5). The importance of TRBP to Dicer-RISC activities was revealed by findings that intracellular depletion of TRBP led to a loss in the RNA silencing function of the cell (5). As yet, the exact details of how loss of TRBP leads to suppression of RNAi remain incompletely understood and somewhat contested (13, 14); however, consistent with TRBP's the currently inferred physiological role of TRBP in the defense against foreign nucleic acids of the cell, this protein was first cloned and identified by us based on its avid binding to a small HIV-1 hairpin RNA, TAR (15). TAR is the trans-activation-responsive RNA sequence (15), which is located in the R region of the HIV-1 LTR and is present twice (once at the 5' end and another time at the 3' end) in all HIV-1 transcripts. TAR forms a stem-bulge-loop RNA structure (16), which is required for recognition by the HIV-1 Tat protein and cellular factor P-TEFb in order for viral transcription to occur efficiently (17, 18).

In principle, the interferon (IFN)-protein kinase R (PKR) network and RNAi constitute two formidable defenses in mammalian cells against viral nucleic acids. Curiously, in practice, most viruses replicate well, once they have gained entry into mammalian cells. This empiricism suggests that viruses may likely have evolved ways to solve the restrictions imposed by RNAi and IFN-PKR. Indeed, the literature contains many examples of viral means employed to neutralize IFN-PKR. These include vaccinia virus E3L protein binding to dsRNAs making them unavailable for PKR activation (19), HCV envelope protein 2 (E2), and nonstructural 5A (NS5A)-mediated direct suppression of the kinase activity of PKR (20) and HIV TAR- (21) and Tat- (22) based attenuation of PKR function. Perhaps not unexpected, there is now increasing evidence that plant and animal viruses can also manipulate the RNAi defense of the cell (2, 6, 23). Toward the latter goal, viruses can mutate both their primary nucleic acid sequences and secondary RNA structures to evade complementarity-based targeting (24); and many viruses also encode suppressor factors (25–30) that interfere with discrete steps in the RNA silencing machinery of the cell.


Figure 1
View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 1.
In vitro transcribed wtTAR is active when transfected into cells and inhibits Dicer activity. A, Structure of wtTAR and mutTAR, constructed by introducing nucleotides changes (sequence in light gray) that disrupted the stem. An example of in vitro transcribed [32P]UTP RNAs is shown (right panel). B, HeLa cells stably integrated with an HIV-LTR-luciferase reporter were transfected with pTat (100 ng) and pCMV-beta-galactosidase. Cells were also co-transfected with increasing concentrations (50 and 500 ng) of in vitro synthesized wtTAR or mTAR RNAs. After 48 h, luciferase activities were quantified and normalized to beta-galactosidase. Results are represented as percentage of control luciferase activity. Values represent averages ± standard deviations from at least three independent transfections. C, ACH2 cells were activated by phorbol 12-myristate 13-acetate (PMA;1 µM) and 293T cells were transfected with 0.5 µg of pNL4–3 or 50 or 500 ng of in vitro synthesized TAR RNA. 48 h later, total cellular RNAs were purified, and 30 µg of each total cellular RNA were analyzed by Northern blotting using a TAR-specific probe.

 
Based on the recent finding that TRBP plays an essential role in the Dicer-RISC activities of the cell(12), and because TAR is the highly abundant HIV-1-encoded RNA originally characterized as a tight TRBP-substrate (15), we wondered if TAR RNA could be a means used by HIV-1 to defeat the RNAi defense of the cell. Here, we show that intracellular TAR RNA can decoy TRBP from Dicer-RISC and reduce RNA silencing in human cells.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
 REFERENCES
 
Plasmids and Reporters—Plasmids were pGL2-luciferase (Invitrogen), pEGFP-C1, pCMV-beta-galactosidase (Clontech), and TAR (15). pcDNA-Dicer-myc vector was from Dr. Patrick Provost (31). Luciferase activity and GFP fluorimetry were measured 48 h after transfection (29).

In vitro Dicer Assay—293T cells were transfected with pcDNA-Dicer-myc with or without RNA using Lipofectamine 2000. 48 h later, cells were lysed (50 mM Hepes, pH 7.3, 50 mM NaCl, 1 mM EDTA, 0.4% Nonidet P-40) and incubated with anti-myc beads (Sigma) (31). 1 µg of 700-bp [32P]UTP dsRNA was incubated for 4 h with immunoprecipitated Dicer-myc. The RNA products were purified and analyzed on a 15% native polyacrylamide gel.

Quantitative Real-time RT-PCR—Small RNAs (<200 bp) were isolated using mirVana miRNA kit (Ambion). miRNA quantitation was as described previously (32, 33). RNA was polyadenylated with ATP by poly(A) polymerase at 37 °C for 1 h using the RNA tailing kit (Ambion) and reverse transcribed using 0.5 µg of poly(T) adapter primer (Invitrogen). For each PCR, equal amounts of cDNA (first normalized using the snU6 RNA) were mixed with SYBR Green PCR mix (Applied Biosystems) and 5 pmol of forward primer (designed on the entire tested miRNA sequence) and reverse primer (based on the adapter sequence). Amplification was for 15 s at 95 °C and 1 min at 60 °C for 55 cycles in an Opticon real-time PCR detection system (Bio-Rad) (32).


   RESULTS AND DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
REFERENCES
 
TAR Inhibits Processing of RNA Hairpins in Cells—TRBP binds TAR RNA with high affinity (15). We reasoned that a surfeit of TAR RNA may act to sequester TRBP, shunting the latter away from Dicer-siRNA-RISC complexes. Others have found that intracellular depletion of TRBP diminishes RISC-mediated gene silencing (12); and our reasoning predicts that TAR overexpression could similarly suppress Dicer-RISC-function.

To test the above, we assessed the effect of increased TAR RNA on TRBP-dependent activity. To model the situation seen in an HIV-infected cell, we transcribed in vitro wild type TAR RNA (wtTAR) and a control mutant (mutTAR) RNA with a disrupted duplexed-hairpin (Fig. 1A). The transcribed RNAs were purified and transfected into cells. To verify that transfected RNAs functioned inside the cell, we first assayed them for the well described ability of TAR to decoy Tat from its transactivation of the HIV-1 LTR (Fig. 1B). Using a HeLa cell line stably integrated with an HIV-LTR-luciferase reporter, which was transiently transfected with a Tat-plasmid, the level of luciferase was measured. We found that Tat transactivation of the LTR reporter was reduced in a dose-dependent manner (up to 60%) by the provision of transfected TAR RNA in trans. As control, mutTAR RNA, which was engineered to be incapable of forming a stable stem-bulge-loop hairpin, did not reduce the transactivation of the LTR-luciferase reporter of Tat. These results support that transfected TAR RNA is intact and functionally active inside cells. We also checked that the amounts of TAR RNA that we transfected into cells are approximate to the level of viral RNAs expressed from an integrated HIV-1 provirus. In Fig. 1C, we demonstrated by Northern blotting that the intracellular level of transfected TAR RNA is in the same range of expression as HIV-1 RNAs transcribed from an intact latent proviral genome in the ACH2 cell line (34) after induction with phorbol 12-myristate 13-acetate.


Figure 2
View larger version (56K):
[in this window]
[in a new window]
  		FIGURE 2.
TAR RNA inhibits Dicer activity. A, 293T cells were transfected with 500 ng of pcDNA-Dicer-myc with increasing amounts of wtTAR (lanes 3–5) or mutant TAR RNA (lanes 8 and 9). TRBP was co-transfected with 1 µgof TAR in lane 6 or transfected alone in lane 10. 48 h later, Dicer immunoprecipitation was assessed by Western blotting using a monoclonal anti-Dicer antibody (lower panels). 1 µg of 700-bp [32P]UTP dsRNA was incubated for 4 h with the respectively immunoprecipitated myc-Dicer. Digested RNA products were analyzed on a 15% native polyacrylamide gel (upper panel), and intensities of the siRNA GFP product were quantified. B, 293T cells were co-transfected with 500 ng of pcDNA-Dicer-myc with increasing amounts of wtTAR (as indicated, lanes 2–5) and 500 ng of pCMV TRBP. Dicer was immunoprecipitated using anti-myc beads, and the amount of TRBP associated was analyzed by Western blot using a rabbit anti-TRBP antibody.

 
We next asked how transfected TAR RNA might impact Dicer activity. For this aim, 293 cells were transfected with a myc-tagged Dicer construct with or without wtTAR RNA. 48 h later, using anti-myc beads, we immunoprecipitated myc-Dicer, and Dicer activity was tested in vitro using a 32P-labeled long GFP dsRNA as substrate (Fig. 2). We observed that myc-Dicer immunoprecipitated from control myc-Dicer-transfected cells efficiently processed long GFP-dsRNA (700 bp) to short (22 nucleotides) GFP-siRNA. However, parallel cells, which were co-transfected with myc-Dicer plus wtTAR RNA, yielded immunoprecipitated myc-Dicer that exhibited a wtTAR-dependent attenuation in dsRNA processing activity (Fig. 2A, lanes 3–5). That the reduction in Dicer activity is due to a TAR-TRBP effect rather than a direct TAR-Dicer effect was supported by findings from co-transfection of a TRBP expression vector into wtTAR+myc-Dicer cells. Supplying TRBP in this way partially restored the RNA processing activity to myc-Dicer (Fig. 2A, lane 6), which was originally suppressed by wtTAR. We performed two control experiments, which demonstrated that transfection into cells of either mutant TAR RNA or TRBP alone showed any effect on the processing activity of immunoprecipitated myc-Dicer (Fig. 2A, lanes 7–10). Consistent with a published report (35), none of our manipulations destabilized Dicer since the amounts of immunoprecipitated Dicer appeared to be uniform in all samples (see Fig. 2A, bottom Western blottings, Dicer). While other interpretations are possible, these results are consistent with wtTAR RNA decoying or occluding TRBP from Dicer leading to reduced dsRNA-processing activity of immunoprecipitated myc-Dicer. That TAR RNA might sequester TRBP to make it less accessible to Dicer was checked by monitoring the amount of TRBP bound to Dicer when TAR was transfected into cells. Indeed, we observed a dose-dependent reduction in the amounts of TRBP that co-immunoprecipitated with Dicer from cells transfected with TAR RNA (Fig. 2B, see lanes 1–5).

TAR Interferes with Intracellular Luc- and GFP-shRNA Activity—We next asked if the ability to reduce in vitro Dicer activity correlated with a capacity to lower intracellular RNA silencing function. To address this point, two previously characterized reporter systems were used to evaluate the effect of TAR RNA on RNAi function. We employed the pGL2 luciferase (Luc-shRNA (short hairpin RNA)) (Fig. 3A) and the CMV GFP (GFP-shRNA) (Fig. 3C) assays (29). When co-expressed, Luc-shRNA inhibited luciferase (luc) mRNA expressed from the pGL2 plasmid by 83%. Intriguingly, when wtTAR was titrated into cells, the ability of Luc-shRNA to silence Luc-mRNA was blunted. Hence, when we introduced 500 ng of wtTAR into cells, the silencing effect of Luc-shRNA dropped from 83 to 44% (Fig. 3A, middle bars). This reduction is specific to wtTAR since the sequence altered TAR mutant did not perturb the silencing activity of Luc-shRNA (Fig. 3A, +mutant TAR lanes).

The effect of TAR on the silencing function of Luc-shRNA might be explained by the sequestration of the former of the limiting amount of TRBP of the cell. If such were to occur, we reasoned that TRBP-dependent Dicer-RISC function should be affected. To verify this reasoning, we transfected increasing amounts of TRBP-plasmid into wtTAR+ Luc-shRNA cells. Interestingly, whereas wtTAR suppressed the action of Luc-shRNA, we found that the ability of Luc-shRNA to silence Luc-mRNA became progressively restored with increasing doses of transfected TRBP (Fig. 3B). Since TRBP has no effect on the transcription from the SV40 promoter in pGL2 (data not shown), these results support the interpretation that exogenous TRBP complemented the function lost due to endogenous TRBP being sequestered by TAR.

We next checked the pGL2 luciferase (Luc-shRNA) findings using the CMV EGFP (EGFP-shRNA) pairing. We found that EGFP-shRNA effectively inhibited EGFP fluorescence up to 79% as observed by microscopy and quantified by fluorimetry (Fig. 3C). Here, wtTAR RNA (Fig. 3C, panels 3 and 4), but not mutant TAR RNA (Fig. 3C, panel 7), when co-expressed led to a 3-fold reduction in the silencing activity of EGFP-shRNA. Co-transfection of exogenous TRBP countermanded the RNAi suppressive activity of wtTAR RNA (compare Fig. 3C, panel 3 versus panel 5, and panel 4 versus panel 6), but transfected TRBP in the context of mutTAR RNA did not affect the activity of EGFP-shRNA (Fig. 3C, panel 8). As additional controls, neither TAR alone nor TRBP alone significantly affected EGFP fluorescence (Fig. 3C, panels 9 and 10). Collectively, the luciferase and EGFP findings are consistent with TAR RNA targeting TRBP to interfere with the RNAi of the cell.

TAR Affects Cellular miRNA Expression—HIV-1 encodes a viral RNA-binding protein, Tat, which partially suppresses the Dicer function of the cell (29). The above reporter assays (Figs. 1 and 3) suggest that HIV-1 may additionally use a viral RNA, TAR, to target TRBP. Because reporter assays may occasionally yield unrepresentative findings, we wished to employ a more physiological readout to assess the consequence of TAR-TRBP interaction. In this regard, in addition to processing artificially constructed shRNA, TRBP-Dicer is involved in authentic processing of the miRNAs of the cell. Hence, we asked whether TAR has an effect on TRBP-Dicer function when assessed in the context of the miRNA maturation of the cell.


Figure 3
View larger version (53K):
[in this window]
[in a new window]
  		FIGURE 3.
TAR overexpression supresses Luc- and GFP-shRNA mediated interference activity. A, cells were co-transfected with pGL2-luciferase + CMV beta-galactosidase and two discrete Luc-shRNAs (1.5 µg each) with increasing wtTAR or mTAR (50 and 500 ng) RNA. B, 0.5–2 µg of pCMV-TRBP were co-transfected in the presence of wtTAR+ Luc-shRNA. C, HeLa cells were transfected with pEGFP (panel 1) and EGFP-shRNA (panel 2), as indicated, with increasing wtTAR (panels 3 and 4), mutTAR (panel 7), wtTAR + TRBP (panels 5 and 6), or mutTAR + TRBP (panel 8). As additional controls, TRBP alone (panel 10) or TAR alone (panel 9) was transfected with pEGFP without EGFP-shRNA into cells. Fluorescence was visualized and quantified by fluorimetry, normalized to beta-galactosidase. Results are represented as percentage of control luciferase activity in the absence of Luc-shRNA (in A), in the presence or wtTAR+Luc-siRNA (in B) or EGFP fluorescence inhibition in the presence of EGFP-shRNA (in C). Values are averages ± standard deviation (where indicated) from at least three independent transfections.

 


Figure 4
View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 4.
wtTAR RNA reduces the abundance of mature cellular miRNAs. miR-16, miR-93, or miR-221 abundance was assessed by quantitative real-time RT-PCR in HeLa cells transfected with wtTAR or mutTAR RNA with U6 snRNA included for normalization of the samples. Signals for each of the PCR cycles (x axis) were collected and converted into log10 values (Y values). CT (threshold cycle) determines the minimum PCR cycles required for the reaction to give a threshold signal. Samples with more templates require fewer PCR cycles to reach the threshold. Relative miRNA expression ratios were quantified using MiniOpticonTM system software. Essentially, the expression ratio between two samples is equal to 2–{Delta}CT, where {Delta}CT is the difference in CT between the two samples. After checking that the reaction efficiencies are equivalent, relative expression analysis are performed by comparing the expression in the sample to mock transfected cells (fixed as the calibrator). Results are expressed in the text as fold differences.

 
Earlier, we reported that transfection of an infectious HIV molecular clone into cells reduced the abundance of many mature human miRNAs (33). Retrospectively, such findings could be explained by TAR RNA expressed from transfected HIV-1 molecular clone modulating the TRBP function of the cell, which is required for miRNA maturation. Previously (33), the three human miRNAs most notably suppressed by HIV-1 were miR-16, miR-93, and miR-221 (21). To ask if TAR RNA alone can explain all or part of the effect on miRNA processing of HIV-1, we used these three miRNAs as readouts in cells transfected singly with wtTAR or mTAR RNA. Mature miR-16, miR-93, and miR-221 were measured using quantitative real-time RT-PCR (32) with internal normalization to an invariant U6 snRNA control (Fig. 4). Provocatively, while the level of the U6 snRNA was unchanged, miR-16, miR-93, and miR-221 were all down-regulated in the presence of wtTAR, but not mutant TAR, by 5.5-, 3.6-, and 38.5-fold, respectively. Viewed collectively with its effect on shRNA maturation, the effect of TAR RNA on miRNA processing suggests that it acts at a step shared by both pathways (i.e. TRBP-Dicer).

For survival, viruses apparently have evolved varied and complex stratagems to neutralize the RNAi-antiviral defense of the cell (26, 29). Previously, it was described that viruses can escape base pair complementarity-mediated attack through mutations in viral genomes, which alter primary sequences and secondary structures (24, 36, 37). Additionally, viruses can also encode proteins that interfere negatively with various steps of the si/miRNA processing machinery of the cell (2). Here we provide the first evidence that HIV-1 could use an abundantly expressed RNA to attenuate antiviral RNAi by targeting TRBP, a key component of Dicer-RISC complexes. It makes sense that HIV-1 might use TAR, since this RNA sequence is found in all viral transcripts, twice. However, we should point out that our current study employed tranfected TAR RNA, and the true biological role of virally transcribed TAR in the miRNA pathway in HIV-1 infected cells requires further study. We anticipate that with further investigation many other viruses may also be found to use decoy RNAs to quell the RNAi defenses of the cell. Indeed, the adenovirus RNA polymerase III transcribed VA RNA has been proposed to quench Dicer function through binding (30), (38). Unlike TAR, VA acts not via TRBP but by direct contact to Dicer (30).

We note with interest that PACT, a human dsRNA-binding protein related to TRBP, has been identified recently to provide a si/miRNA processing function partially redundant to TRBP (39). Because PACT and TRBP conserve RNA-binding domains, in principle, excess TAR RNA can also sequester PACT and inhibit PACT activity. Because a part of PACT activity is divergent from TRBP activity in si/miRNA processing, this fact may explain why exogenous complementation of TRBP only partially restored wtTAR RNA-mediated suppression of Luc- and GFP-shRNA interference activity (Fig. 3). Our current understanding of Tat, TAR, VA, TRBP, PACT, and Dicer leaves unresolved many details about how small viral dsRNAs, viral dsRNA-binding proteins (40), and cellular dsRNA-binding proteins interact either cooperatively (41) or antagonistically (6, 27–29, 42) in si/miRNA pathways. Nevertheless, an emerging view is that viruses can use both viral proteins and RNAs to combat the RNAi defense of the cell.


   FOOTNOTES
 
* This work was supported through intramural funding from the NIAID, National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Molecular Virology Section, Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bldg. 4, Rm. 306, 9000 Rockville Pike, Bethesda, MD 20892-0460. Tel.: 301-496-6680; Fax: 301-480-3686; E-mail: kj7e{at}nih.gov.

2 The abbreviations used are: RNAi, RNA interference; dsRNA, double-stranded RNA; siRNA, small interfering RNA; TRBP, TAR RNA-binding protein; RISC, RNA-induced silencing complex; Ago2, argonaute 2; miRNA, microRNA; IFN, interferon; PKR, protein kinase R; HIV-1, human immunodeficiency virus, type 1; GFP, green fluorescent protein; EGFP, enhanced GFP; RT, reverse transcription; LTR, long terminal repeat; wt, wild type; shRNA, short hairpin RNA; CMV, cytomegalovirus. Back


   ACKNOWLEDGMENTS
 
We thank Dr. A. Dayton and members of our laboratory for reading the manuscript and Dr. A. Buckler-White and R. Plishka for sequencing.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Le Page, C., Genin, P., Baines, M. G., and Hiscott, J. (2000) Rev. Immunogenet. 2, 374–386[Medline] [Order article via Infotrieve]
  2. Voinnet, O. (2005) Nat. Rev. Genet. 6, 206–220[CrossRef][Medline] [Order article via Infotrieve]
  3. Haase, A. D., Jaskiewicz, L., Zhang, H., Laine, S., Sack, R., Gatignol, A., and Filipowicz, W. (2005) EMBO Rep. 6, 961–967[Medline] [Order article via Infotrieve]
  4. Forstemann, K., Tomari, Y., Du, T., Vagin, V. V., Denli, A. M., Bratu, D. P., Klattenhoff, C., Theurkauf, W. E., and Zamore, P. D. (2005) PloS Biol. 3, e236[CrossRef][Medline] [Order article via Infotrieve]
  5. Chendrimada, T. P., Gregory, R. I., Kumaraswamy, E., Norman, J., Cooch, N., Nishikura, K., and Shiekhattar, R. (2005) Nature 436, 740–741[CrossRef][Medline] [Order article via Infotrieve]
  6. Yeung, M. L., Bennasser, Y., Le, S. Y., and Jeang, K. T. (2005) Cell Res. 15, 935–946[CrossRef][Medline] [Order article via Infotrieve]
  7. Liu, J., Valencia-Sanchez, M. A., Hannon, G. J., and Parker, R. (2005) Nat. Cell Biol. 7, 719–723[CrossRef][Medline] [Order article via Infotrieve]
  8. Sen, G. L., and Blau, H. M. (2005) Nat. Cell Biol. 7, 633–636[CrossRef][Medline] [Order article via Infotrieve]
  9. Meister, G., Landthaler, M., Peters, L., Chen, P. Y., Urlaub, H., Luhrmann, R., and Tuschl, T. (2005) Curr. Biol. 15, 2149–2155[CrossRef][Medline] [Order article via Infotrieve]
  10. Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., Hammond, S. M., Joshua-Tor, L., and Hannon, G. J. (2004) Science 305, 1437–1441[Abstract/Free Full Text]
  11. Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng, G., and Tuschl, T. (2004) Mol. Cell 15, 185–197[CrossRef][Medline] [Order article via Infotrieve]
  12. Gregory, R. I., Chendrimada, T. P., Cooch, N., and Shiekhattar, R. (2005) Cell 123, 631–640[CrossRef][Medline] [Order article via Infotrieve]
  13. Gatignol, A., Laine, S., and Clerzius, G. (2005) Retrovirology 2, 65[CrossRef][Medline] [Order article via Infotrieve]
  14. Rossi, J. J. (2005) EMBO Rep. 6, 927–929[CrossRef][Medline] [Order article via Infotrieve]
  15. Gatignol, A., Buckler-White, A., Berkhout, B., and Jeang, K. T. (1991) Science 251, 1597–1600[Abstract/Free Full Text]
  16. Berkhout, B., and Jeang, K. T. (1991) Nucleic Acids Res. 19, 6169–6176[Abstract/Free Full Text]
  17. Rana, T. M., and Jeang, K. T. (1999) Arch. Biochem. Biophys. 365, 175–185[CrossRef][Medline] [Order article via Infotrieve]
  18. Brady, J., and Kashanchi, F. (2005) Retrovirology 2, 69[CrossRef][Medline] [Order article via Infotrieve]
  19. Davies, M. V., Chang, H. W., Jacobs, B. L., and Kaufman, R. J. (1993) J. Virol. 67, 1688–1692[Abstract/Free Full Text]
  20. He, Y., and Katze, M. G. (2002) Viral. Immunol. 15, 95–119[CrossRef][Medline] [Order article via Infotrieve]
  21. Park, H., Davies, M. V., Langland, J. O., Chang, H. W., Nam, Y. S., Tartaglia, J., Paoletti, E., Jacobs, B. L., Kaufman, R. J., and Venkatesan, S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4713–4717[Abstract/Free Full Text]
  22. Brand, S. R., Kobayashi, R., and Mathews, M. B. (1997) J. Biol. Chem. 272, 8388–8395[Abstract/Free Full Text]
  23. Saumet, A., and Lecellier, C. H. (2006) Retrovirology 3, 3[CrossRef][Medline] [Order article via Infotrieve]
  24. Westerhout, E. M., Ooms, M., Vink, M., Das, A. T., and Berkhout, B. (2005) Nucleic Acids Res. 33, 796–804[Abstract/Free Full Text]
  25. Kasschau, K. D., and Carrington, J. C. (1998) Cell 95, 461–470[CrossRef][Medline] [Order article via Infotrieve]
  26. Voinnet, O., Pinto, Y. M., and Baulcombe, D. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 14147–14152[Abstract/Free Full Text]
  27. Ye, K., Malinina, L., and Patel, D. J. (2003) Nature 426, 874–878[CrossRef][Medline] [Order article via Infotrieve]
  28. Lecellier, C. H., Dunoyer, P., Arar, K., Lehmann-Che, J., Eyquem, S., Himber, C., Saib, A., and Voinnet, O. (2005) Science 308, 557–560[Abstract/Free Full Text]
  29. Bennasser, Y., Le, S. Y., Benkirane, M., and Jeang, K. T. (2005) Immunity 22, 607–619[CrossRef][Medline] [Order article via Infotrieve]
  30. Lu, S., and Cullen, B. R. (2004) J. Virol. 78, 12868–12876[Abstract/Free Full Text]
  31. Provost, P., Dishart, D., Doucet, J., Frendewey, D., Samuelsson, B., and Radmark, O. (2002) EMBO J. 21, 5864–5874[CrossRef][Medline] [Order article via Infotrieve]
  32. Shi, R., and Chiang, V. L. (2005) BioTechniques 39, 519–525[Medline] [Order article via Infotrieve]
  33. Yeung, M. L., Bennasser, Y., Myers, T., Jiang, G., Benkirane, M., and Jeang, K. T. (2005) Retrovirology 2, 81[Medline] [Order article via Infotrieve]
  34. Folks, T. M., Clouse, K. A., Justement, J., Rabson, A., Duh, E., Kehrl, J. H., and Fauci, A. S. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2365–2368[Abstract/Free Full Text]
  35. Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Radmark, O., Kim, S., and Kim, V. N. (2003) Nature 425, 415–419[CrossRef][Medline] [Order article via Infotrieve]
  36. Das, A. T., Brummelkamp, T. R., Westerhout, E. M., Vink, M., Madiredjo, M., Bernards, R., and Berkhout, B. (2004) J. Virol. 78, 2601–2605[Abstract/Free Full Text]
  37. Bennasser, Y., Yeung, M. L., Benkirane, M., and Jeang, K. T. (2006) Curr. Opin. HIV AIDS 1, 208–211
  38. Andersson, M. G., Haasnoot, P. C., Xu, N., Berenjian, S., Berkhout, B., and Akusjarvi, G. (2005) J. Virol. 79, 9556–9565[Abstract/Free Full Text]
  39. Lee, Y., Hur, I., Park, S. Y., Kim, Y. K., Suh, M. R., and Kim, V. N. (2006) EMBO J. 25, 522–532[CrossRef][Medline] [Order article via Infotrieve]
  40. Lichner, Z., Silhavy, D., and Burgyan, J. (2003) J. Gen. Virol. 84, 975–980[Abstract/Free Full Text]
  41. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., and Sarnow, P. (2005) Science 309, 1577–1581[Abstract/Free Full Text]
  42. Kasschau, K. D., Xie, Z., Allen, E., Llave, C., Chapman, E. J., Krizan, K. A., and Carrington, J. C. (2003) Dev. Cell 4, 205–217[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
D. L. Ouellet, I. Plante, P. Landry, C. Barat, M.-E. Janelle, L. Flamand, M. J. Tremblay, and P. Provost
Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element
Nucleic Acids Res., April 1, 2008; 36(7): 2353 - 2365.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
A. A. Matskevich and K. Moelling
Dicer is involved in protection against influenza A virus infection
J. Gen. Virol., October 1, 2007; 88(10): 2627 - 2635.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Berkhout and K.-T. Jeang
RISCy Business: MicroRNAs, Pathogenesis, and Viruses
J. Biol. Chem., September 14, 2007; 282(37): 26641 - 26645.
[Full Text] [PDF]

Home page
 J. Virol.Home page
A. T. Das, A. Harwig, M. M. Vrolijk, and B. Berkhout
The TAR Hairpin of Human Immunodeficiency Virus Type 1 Can Be Deleted When Not Required for Tat-Mediated Activation of Transcription
J. Virol., July 15, 2007; 81(14): 7742 - 7748.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. H. Kok, M.-H. J. Ng, Y.-P. Ching, and D.-Y. Jin
Human TRBP and PACT Directly Interact with Each Other and Associate with Dicer to Facilitate the Production of Small Interfering RNA
J. Biol. Chem., June 15, 2007; 282(24): 17649 - 17657.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. K. Scott, A. Goga, D. Bhaumik, C. E. Berger, C. S. Sullivan, and C. C. Benz
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b
J. Biol. Chem., January 12, 2007; 282(2): 1479 - 1486.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/38/27674    most recent
C600072200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bennasser, Y.
Right arrow Articles by Jeang, K.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bennasser, Y.
Right arrow Articles by Jeang, K.-T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.